The primary therapeutic role of Элекасол is to provide supportive, symptomatic relief across domains characterized by symptoms related to inflammatory or irritative states. The blend of plant extracts is generally considered relevant when supportive symptom management is appropriate in acute or recurrent episodes.

The preparation is commonly used to help with symptoms linked to organ-specific functional stress in conditions such as gastritis or episodic manifestations of peptic ulcer disease, and is relevant when supportive symptom management is appropriate for inflammatory conditions of the oral cavity and respiratory tract, including stomatitis, gingivitis, and pharyngitis.

Chamomile, a key component of the mixture, is relevant for easing symptoms related to inflammation of the mucous membranes of the mouth and throat, as well as for various gastrointestinal disturbances.

This symptomatic assistance is intended to provide support that assists with maintaining stability during symptom fluctuations in conditions where functional balance becomes affected.

The preparation contributes to easing localized discomfort and may assist with maintaining functional stability when symptoms related to physical discomfort become more noticeable, assisting with recovery from irritative states. It helps to address symptom clusters that create noticeable physiological strain and contributes to easing the overall symptom load.

---

Quick Fact: Symptom Management Focus

Element	Description
Therapeutic Focus	Symptomatic support for mucosal irritation
Conditions Targeted	Gastritis, ulcers, stomatitis, pharyngitis
Benefit Focus	Easing localized discomfort and assisting with healing of irritative states

The eligibility for using Элекасол is strictly defined by official government regulatory documents, which establish clear contraindications based on age, physiological state, and pre-existing medical conditions.

Populations for Whom Use is Contraindicated

Category	Exclusion Criterion (Official Labeling)
Hypersensitivity	Individual intolerance or documented allergy to the preparation's components or to plants of the Asteraceae/Compositae family.
Age	Children under 12 years of age (some sources specify under 3 years).
Internal Use (Physiological State)	Pregnancy and the period of breastfeeding (lactation).
Internal Use (Comorbidities)	Hypokalemia, severe obesity, arterial hypertension, and impaired hepatic or renal function.

Age and Conditional Use Rules

• Eligibility: The medicine is allowed for use by adults and children over 12 years of age.
• Conditional Use: For pregnant or breastfeeding individuals, the medicine is contraindicated for internal administration. It may only be used for external/local application if a physician determines the anticipated benefit to the mother outweighs the potential risk to the fetus or child.
• Restriction: Safety and efficacy have not been formally established for use during pregnancy and lactation, resulting in the official restrictions and contraindications listed above.

The regulatory profile defines eligibility by imposing strict exclusions on specific patient groups, making the medicine unsuitable for pediatric use below the minimum age, and prohibiting its internal use in patients with designated cardiovascular, metabolic, or organ-function conditions.

Interactions with other medicines and products

Regulatory documentation for the components of Элекасол highlights several documented interaction patterns, primarily driven by Licorice and German Chamomile. These interactions are classified as clinically significant due to their potential to modify the effects or exposure of co-administered medicines, requiring specific regulatory cautions.

Documented Pharmacodynamic Interactions

The Licorice component presents a risk for Pharmacodynamic Reinforcement of Hypokalaemia (low potassium levels) with prolonged use. This necessitates official warnings for co-administration with cardiac glycosides (like Digoxin) and hypokalaemia-inducing drugs, including diuretics and corticosteroids, due to the potential for potentiation and electrolyte imbalance. Furthermore, the mild CNS-depressant effects of Chamomile are noted to cause additive sedation when combined with alcohol or other CNS depressants.

Metabolic and Exposure Interactions

Official regulatory syntheses cite the potential for key components to modulate major Cytochrome P450 (CYP) enzymes (e.g., CYP3A4, CYP2C9) and the P-glycoprotein (P-gp) transporter. This pharmacokinetic interaction may lead to altered plasma concentrations (increased or decreased exposure) of co-administered prescription medicines that are substrates for these metabolic or transporter systems. Co-use with stimulant laxatives is also restricted by some national authorities due to the risk of additive potassium loss.

How Элекасол Modulates Inflammatory Signaling

The core anti-inflammatory mechanism involves the inhibition of key enzymes like COX-2 and LOX, alongside the modulation of central signaling pathways such as NF-κB and MAPK. This dual action reduces the cellular production and release of pro-inflammatory mediators (prostaglandins, leukotrienes, and cytokines), a process that ultimately reduces local vascular leakage and cellular activation.

The Antiseptic Mechanism of Cell Disruption

Volatile components within the extracts, such as essential oils, operate by physically compromising the structural integrity of microbial organisms. These lipophilic compounds disrupt the phospholipid bilayer of bacterial and fungal cell membranes, causing the irreversible leakage of intracellular contents and collapse of microbial homeostasis. This process results in the direct inhibition of microbial viability and induced cell lysis at the site of contact.

Antioxidant Constraint on Signaling

Specific phenolic compounds function as antioxidants and free radical scavengers. By neutralizing Reactive Oxygen Species (ROS), the compounds limit radical-mediated oxidation and constrain the associated initiation of inflammatory signaling.

Official Administration and Dosing for Элекасол

Элекасол is classified as a phytopreparation that requires mandatory preparation as an aqueous infusion (or decoction) before use, according to its formulation requirements. The drug is supplied as an herbal Collection (Сбор) or in filter bags, and its usage is structured around both systemic (internal) and local routes of administration.

Administration Scope

Route of Administration	Dosing/Frequency	Preparation and Timing
Systemic (Oral)	1/3 cup of the warm infusion.	3 times per day, administered 30 minutes before meals.
Local/Topical	Varies by procedure (1-5 times daily).	Used for rinsing, irrigations, and microclysters; often diluted 2-4 times with warm water.
Inhalation	2-5 times daily.	Requires the infusion to be warm or hot; cold infusion is avoided due to the risk of bronchospasm.

Preparation Requirements

The preparation process is a mandatory step for use. Approximately 8 g of the loose Collection (or two filter bags) is added to 200 mL of boiling water, followed by a specific heating/infusion time (e.g., 15 minutes boiling, 45 minutes cooling). The strained volume is adjusted back to 200 mL with boiled water. The prepared infusion must be shaken before use and is only stable for storage in a cool place for a maximum of 2 days.

Population-Specific Use

While Элекасол is contraindicated for children under the age of 3, the dose for pediatric patients over 3 years is individualized by a physician. Children over 12 years typically follow the adult internal dose (1/3 cup), taken 3 times daily. The overall course of treatment is determined individually by the physician based on the specific condition.

Research evidence / Overview of Studies for Элекасол

Overview of Studies for Key Components in Mucosal Inflammation

The research supporting the evaluation of the Элекасол preparation primarily focuses on the properties and effects of its individual herbal components, such as Chamomile ( Chamomillae Recutitae Flores) and Licorice ( Glycyrrhizae Radices). Because the preparation is a complex, multicomponent mixture, much of the available evidence is related to the individual extracts.

This body of work includes Systematic Reviews and Meta-analyses that aggregate findings from various Randomized Controlled Trials (RCTs). These studies were applied in research contexts exploring how symptoms are monitored over time in contexts related to inflammatory or irritative states of the oral and pharyngeal (throat) mucosal lining. Researchers examined a variety of component-specific preparations, including mouthwashes and gels, to understand their potential role in evaluating symptom patterns linked to inflammatory or irritative states.

Studies Examining Anti-inflammatory and Tissue Repair Functions

A significant portion of the evidence for the preparation's general anti-inflammatory and reparative classification is derived from foundational science. Studies monitored outcomes linked to inflammatory or irritative states through In vitro (laboratory cell) experiments and research using Animal Models.

Research examined molecular and cellular changes, reporting patterns related to potential antimicrobial activity against certain pathogens and the inhibition of specific biological signals involved in inflammation. These studies contribute to the broader evidence landscape by providing context on the likely mechanism of action of the components. Findings from this pre-clinical research contribute to understanding potential patterns related to tissue health.

Evidence Gaps: Unstudied Areas and Limitations

While research highlights what is known about the components' properties, the evidence base for the multi-component Элекасол preparation itself remains limited and heterogeneous. Sample sizes were modest in many component-specific trials, and evidence quality varies across studies. Comparative evidence is also lacking for the full mixture against standard comparators. The research base is heavily reliant on mechanistic evidence, which explores actions at a molecular level.

Key Studies & References Traditional uses, phytochemistry and pharmacology of licorice (Glycyrrhiza spp.): a review (Used for anti-inflammatory mechanism evidence)

Common questions about Элекасол (FAQ)

Q: Can Элекасол be used by children?

According to official documentation, the preparation is generally contraindicated for children under 12 years of age. While individualized dosing is mentioned for children over the age of three, the official labeling provides the more restrictive age for use. Eligibility for pediatric patients is generally a topic requiring individual professional consultation.

Q: Does alcohol interact with Элекасол?

Regulatory documents describe that the Chamomile component in Элекасол has mild central nervous system (CNS) depressant effects. The official product information notes that combining the preparation with alcohol has the potential for additive sedation.

Q: Can I take Элекасол with my regular vitamins or supplements?

Official regulatory syntheses indicate that components in the preparation may influence metabolic enzymes (such as CYP/P-gp), which can alter how the body processes other substances. Because specific vitamins and supplements are not generally tested for interaction, regulatory cautions indicate that co-use of supplements involves the potential for risk that is best managed through professional oversight.

Q: Is Элекасол available over the counter?

Official product information notes that the overall course of treatment for the drug must be determined individually by a physician. This requirement for professional determination is stated in regulatory documents.

Q: What should I know about storage conditions for Элекасол?

The unprepared collection must be stored in its original packaging, protected from light and moisture, at a temperature not exceeding 25 C. Once the aqueous infusion is prepared, its stability is limited; it must be stored in a cool place (between 8 C and 15 C) and should be used for a maximum of 48 hours (2 days).

Q: What safety classifications are officially noted for Элекасол?

Элекасол is officially classified as a Phytopreparation and a multicomponent herbal drug. This categorization confirms that its properties are derived from a fixed botanical mixture and it belongs to the pharmacological class of anti-inflammatory and antimicrobial agents.

Q: Does Элекасол affect blood pressure or heart rate?

Official labeling lists pre-existing conditions like hypertension (high blood pressure) as a contraindication for internal use. This caution reflects the need to manage potential systemic effects from certain components, particularly the Licorice root, in individuals with cardiovascular concerns.

Q: Are there any warnings about driving or operating machinery while using Элекасол?

The regulatory information notes a component (Chamomile) has mild CNS-depressant effects, which are described as a key consideration for activities requiring focused attention, such as driving or operating machinery.

Q: How is the efficacy of Элекасол measured in research studies?

Research evidence is described as monitoring patterns related to potential antimicrobial activity and specific biological signals involved in inflammation at a cellular level. Studies also explore how symptoms are monitored over time in contexts related to inflammatory or irritative states of the mucosal lining, which contributes to understanding the product’s general purpose.

How to Store and Dispose of Элекасол

Official regulatory guidelines establish distinct storage requirements for the unprepared herbal collection and the finished infusion.

Storage Conditions

The original collection must be stored in its original packaging, in a dry place, and protected from light. The temperature for the collection must not exceed 25 C. The product's shelf life is typically 3 years when stored under these conditions.

Stability of the Prepared Infusion

Once the aqueous infusion is prepared, its stability is limited. The finished infusion must be stored in a cool place (defined as 8 C to 15 C) and must be used for no more than 2 days (48 hours).

Safety and Disposal

The medicine must be kept in a place inaccessible and out of the reach of children. The product must not be used after the expiration date. Specific official instructions for household disposal of unused or expired product are not provided in labeling; disposal should therefore follow standard local waste regulations.